Anthony Nolan Research Institute, Royal Free Hospital, London, United Kingdom; UCL Cancer Institute, Royal Free Campus, London, United Kingdom.
Anthony Nolan Research Institute, Royal Free Hospital, London, United Kingdom.
Biol Blood Marrow Transplant. 2019 Mar;25(3):443-450. doi: 10.1016/j.bbmt.2018.12.768.
HLA matching at an allelic-level resolution for volunteer unrelated donor (VUD) hematopoietic cell transplantation (HCT) results in improved survival and fewer post-transplant complications. Limitations in typing technologies used for the hyperpolymorphic HLA genes have meant that variations outside of the antigen recognition domain (ARD) have not been previously characterized in HCT. Our aim was to explore the extent of diversity outside of the ARD and determine the impact of this diversity on transplant outcome. Eight hundred ninety-one VUD-HCT donors and their recipients transplanted for a hematologic malignancy in the United Kingdom were retrospectively HLA typed at an ultra-high resolution (UHR) for HLA-A, -B, -C, -DRB1, -DQB1, and -DPB1 using next-generation sequencing technology. Matching was determined at full gene level for HLA class I and at a coding DNA sequence level for HLA class II genes. The HLA matching status changed in 29.1% of pairs after UHR HLA typing. The 12/12 UHR HLA matched patients had significantly improved 5-year overall survival when compared with those believed to be 12/12 HLA matches based on their original HLA typing but were found to be mismatched after UHR HLA typing (54.8% versus 30.1%, P = .022). Survival was also significantly better in 12/12 UHR HLA-matched patients when compared with those with any degree of mismatch at this level of resolution (55.1% versus 40.1%, P = .005). This study shows that better HLA matching, found when typing is done at UHR that includes exons outside of the ARD, introns, and untranslated regions, can significantly improve outcomes for recipients of a VUD-HCT for a hematologic malignancy and should be prospectively performed at donor selection.
在志愿无关供者(VUD)造血细胞移植(HCT)中,进行等位基因水平的 HLA 配型可改善生存并减少移植后并发症。用于高度多态性 HLA 基因的分型技术存在局限性,这意味着在 HCT 中尚未对 ARD 之外的变异进行特征描述。我们的目的是探索 ARD 之外的多样性程度,并确定这种多样性对移植结果的影响。
我们回顾性地对 891 名在英国因血液系统恶性肿瘤接受 VUD-HCT 的供者及其受者进行 HLA 超高度分辨率(UHR)分型,使用下一代测序技术对 HLA-A、-B、-C、-DRB1、-DQB1 和-DPB1 进行分型。HLA Ⅰ类基因的匹配在全基因水平上确定,HLA Ⅱ类基因的匹配在编码 DNA 序列水平上确定。在 UHR HLA 分型后,29.1%的供-受者配对的 HLA 匹配状态发生改变。与那些根据原始 HLA 分型被认为是 12/12 HLA 匹配,但在 UHR HLA 分型后被发现不匹配的患者相比,12/12 UHR HLA 匹配的患者 5 年总生存率显著提高(54.8%比 30.1%,P=0.022)。在这一分辨率水平上,与任何程度的不匹配相比,12/12 UHR HLA 匹配的患者的生存率也显著提高(55.1%比 40.1%,P=0.005)。
这项研究表明,在 UHR 进行包括 ARD 之外的外显子、内含子和非翻译区的 HLA 分型,可以显著改善血液系统恶性肿瘤 VUD-HCT 受者的预后,并且应该在供者选择时前瞻性地进行。